DUBLIN, Oct. 2, 2025 – Jazz Pharmaceuticals plc (Nasdaq: JAZZ) announced today that the U.S. Food and Drug Administration (FDA) has approved Zepzelca® (lurbinectedin) in combination with atezolizumab (Tecentriq®) or Tecentriq Hybreza® as a first-line maintenance therapy for adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed following induction therapy with atezolizumab, carboplatin, and etoposide. This landmark approval makes the regimen the first combination therapy approved as maintenance in ES-SCLC, addressing a critical unmet need in this aggressive disease. The approval is based on pivotal results from the Phase 3 IMforte trial, which demonstrated significant benefits in
Immunotherapy progression-free survival (PFS) and overall survival (OS) compared with atezolizumab alone.
Science Significance
The IMforte trial established that the Zepzelca–Tecentriq combination reduced the risk of disease progression or death by 46% and the risk of death by 27% compared with atezolizumab alone. Median overall survival improved to 13.2 months versus 10.6 months, and median progression-free survival extended to 5.4 months versus 2.1 months. These findings underscore the synergy between a DNA-binding alkylating agent (Zepzelca) and immune checkpoint inhibition (atezolizumab). By disrupting tumor cell DNA repair and boosting immune activity, the regimen delivers a novel mechanism of sustained disease control. Experts describe the results as a “meaningful shift” in the therapeutic landscape of ES-SCLC.
Regulatory Significance
The FDA approval establishes the first-ever combination regimen approved for maintenance in ES-SCLC, reinforcing regulatory recognition of the urgent need for improved therapies in this aggressive malignancy. The National Comprehensive Cancer Network® (NCCN®) has already updated its guidelines, listing Zepzelca plus atezolizumab as a preferred maintenance regimen. This rapid alignment between FDA approval and NCCN guidelines ensures immediate availability to oncologists and patients across the United States.
Advertisement
Business Significance
For Jazz Pharmaceuticals, this approval marks a strategic expansion of its oncology portfolio, building upon Zepzelca’s accelerated approval in 2020. By positioning Zepzelca in combination with Roche’s Tecentriq, Jazz strengthens its presence in thoracic oncology and aligns with a partner holding deep immunotherapy expertise. The ES-SCLC maintenance market represents a sizable opportunity, with approximately 30,000 new cases annually in the U.S. The new indication is expected to contribute meaningfully to Jazz’s oncology revenues, broaden the therapeutic adoption of Zepzelca, and differentiate the company in a highly competitive cancer market.
Patients’ Significance
For patients with ES-SCLC, the approval provides a critical new option in a disease known for rapid relapse and limited survival outcomes. Physicians and patient advocates emphasize that extending progression-free survival and delaying relapse translates directly into more meaningful time with families and improved quality of life. As Dr. Roy Herbst of Yale Cancer Center noted, the regimen offers “a proactive approach shown to improve progression-free and overall survival” in a setting where uncertainty after induction therapy has long frustrated patients and clinicians.
Policy Significance
This FDA action highlights the importance of sustained investment in novel drug–immunotherapy combinations. The early guideline adoption by NCCN further demonstrates how regulators and policymakers are accelerating access to innovations with strong clinical data. The approval could also influence reimbursement frameworks by payers, given the combination’s demonstrated improvement in survival metrics, setting the stage for broader health-system acceptance.
Transaction Highlights
The FDA approval of Zepzelca plus atezolizumab marks the first maintenance combination approved for ES-SCLC. The decision is supported by the Phase 3 IMforte trial, which showed that the regimen reduced risk of disease progression or death by 46% and risk of death by 27% compared to atezolizumab alone. Patients on the combination achieved a median OS of 13.2 months versus 10.6 months and median PFS of 5.4 months versus 2.1 months. The NCCN has updated its guidelines to recommend the regimen as a preferred maintenance therapy in patients who have not progressed after induction chemotherapy. This update provides immediate integration into clinical practice, ensuring rapid patient access with this approval, Jazz Pharmaceuticals advances its oncology strategy and strengthens its collaboration with Genentech/Roche in immuno-oncology. The development marks a major milestone in Jazz’s mission to expand treatment options in oncology, offering physicians and patients an important new tool in managing ES-SCLC.
Source: Jazz Pharmaceuticals plc Press Release
